Prop 65 Compliance for Fish Oil Supplements (PCBs + Dioxins/Furans + Methylmercury + GOED-Equivalent Defensibility)

Why Fish Oil Sits at the Heart of Prop 65

Fish oil is the most-litigated supplement category in Prop 65 history. The category’s plaintiff playbook was established by the 2010 Manthey v. CVS Pharmacy case, which named multiple brands and retailers and created a repeatable enforcement template focused on PCBs.

Fish Oil Is a Proven, Ongoing Target

The brief emphasizes that omega‑3 enforcement continues, especially for brands outside the GOED consent judgment. PCBs and related fat-bound contaminants can vary dramatically by species, origin, and refining method.

• PCB cancer NSRL: 90 ng/day (orders of magnitude below FDA’s 2 ppm food tolerance)
• Brand-to-brand spread: products tested across the market ranged roughly 12 ng to 850+ ng PCB per dose (origin/refining drive the delta)
• Target set: PCBs, dioxins/furans, and methylmercury drive omega‑3 enforcement

How Contamination Reaches the Capsule

Ocean sediment → fish fat → crude oil → refined product. Each stage is a control point, but the brief is clear: fish oil is the fat contaminants concentrate in—and refining is the only real defense.

• Ocean sources: PCBs, dioxins, and methylmercury persist from legacy industrial pollution
• Fish fat uptake: lipophilic contaminants bioaccumulate in fat—the same fat extracted for omega‑3
• Crude fish oil: contains full contaminant load before refining
• Refined capsule: molecular distillation can reduce PCBs 90%+, but only if executed and verified per lot

Inside the Benchmark, or Outside It?

The brief distinguishes between GOED-consent-judgment signatories and non-signatory brands. For non-signatories, plaintiffs may argue a “default-zero” approach unless you can prove a defensible safe-harbor position.

• GOED-settlement brands: operate with settlement limits, consent-based protection, and standardized testing options
• Non-signatory brands: face “default-zero” arguments; burden of proof shifts to the brand; limits can be re-litigated case by case

A private compliance system can replicate GOED-level defensibility without requiring membership—by building the documentation and per-lot verification a plaintiff discovery request expects.

Business Impact of Non-Compliance

• 60-Day Notice of Violation: 15+ years of plaintiff infrastructure targeting fish oil makes enforcement highly repeatable
• Multi-defendant settlement range: settlements can run $25K–$150K per SKU (multi-SKU portfolios multiply exposure)
• Retailer pressure: Whole Foods, Sprouts, CVS, and Amazon require documented compliance for omega‑3 listings
• Premium brand damage: “pharmaceutical‑grade,” “purified,” and “clean” claims are undercut by defensive warnings

Why Prop65Compliance.com

• Compliance-focused: we don’t litigate—we build the system that prevents litigation
• System-based approach: testing a single batch doesn’t protect you; a per-lot documented program does
• Managed by Consultare Inc. Group: operational oversight from a dedicated compliance management team
• Built on SystemsBuilder + InterlinkIQ: artifact-based system, document control, and AI-assisted workflows

What We Deliver

An end-to-end Prop 65 program calibrated to the most-litigated supplement category—documented, traceable, and audit-ready per lot, per species, per refiner.

• Species-level risk assessment
• PCB, dioxin & Hg testing oversight
• Per-dose exposure math
• Compliance determination
• Warning label strategy
• Supplier & refiner program
• Documentation system
• Ongoing monitoring

Core Technical Components

• PCB congener panel: 209-congener PCB analysis (USEPA Method 1668C) aligned to Prop 65’s 90 ng/day PCB cancer NSRL and dioxin-like PCB limits
• Dioxin & furan TEQ analysis: 2,3,7,8‑TCDD toxic equivalency quotient (USEPA 1613) consistent with consent-judgment defensibility expectations
• Methylmercury speciation: total Hg and methylmercury (the toxicologically relevant form for reproductive-toxicity exposure math)
• Species & origin documentation: small cold-water fish vs larger species have different contamination profiles
• Per-lot compliance file: species inputs, crude-oil COA, post-distillation verification, final-product determination, warning decision

Boat-to-Bottle Supply-Chain Control

Species, origin, and refining method drive the contamination profile—compliance tracks all three.

• Species & origin: each origin/species has a distinct contaminant profile
• Refiner qualification: molecular distillation capability, contaminant stripping verification, and GMP documentation
• Per-lot COA tracking: crude-oil and finished-oil COAs verified per lot; refining claims must be documented, not assumed
• Supplier CAPA: out-of-spec lots trigger corrective actions (supplier rotation, re-distillation, or lot rejection)

The SystemsBuilder Approach (Artifacts vs Records)

Artifact-based compliance is built once and scales across every lot and every species input. You pay for the structure—not the records.

• Artifact (you pay): PCB/Dioxin Verification Program defining how every species, refiner, and lot is screened and documented
• Records (no added cost): per-lot, per-SKU records generated within the same framework

How It Works (Three Phases)

Step 01 — Setup

• SKU & species scoping
• Refiner & origin mapping
• Testing plan per lot
• Documentation structure

Step 02 — Implementation

• Lab coordination (ISO/IEC 17025)
• PCB, dioxin, Hg testing
• Per-lot determination
• Warning-label decisions

Step 03 — Monitoring

• Monthly compliance oversight
• Per-lot & per-refiner review
• Refiner-change re-determinations
• Audit-ready reporting

Pricing (As Presented in the Brief)

Compliance System Setup (One-Time Investment)

• $1,500 — up to 3 omega-3 SKUs
• + $150 — each additional SKU (concentration / form / blend)

Setup includes: species-level risk assessment, PCB/dioxin/Hg testing program, per-dose exposure framework, documentation system setup, and compliance determination structure.

Monthly Monitoring (Ongoing Oversight)

• $500/month — up to 7 SKUs
• + $50/month — per additional SKU

Monitoring includes: per-lot test review, refiner-change re-determinations, monthly reporting, and trend analysis by refiner. Cancel anytime. No long-term contracts.

Testing Monitoring Fees (Per-Event Oversight)

• $35 per testing monitoring event (per lot / per analyte)
• Lab fees excluded: testing performed by independent ISO/IEC 17025 accredited laboratories; lab costs billed directly by the laboratory

What You Receive

• Per-lot compliance determinations: PCB/dioxin/Hg review with pass/fail determination and reviewer sign-off
• Monthly summary reports: snapshot of SKUs, refiner trends, testing events, and open action items
• Compliance monitoring logs: date-stamped log of every decision made
• Refiner & species records: attestations, COAs, distillation verification, corrective actions by supplier and species
• Audit-ready documentation: packaged for OAG inquiries, retailer audits, and Amazon compliance requests on short notice

Built for Defensibility

The 2010 lawsuit’s burden-of-proof standard still applies to non-GOED brands today—defensibility is documentation plus verified testing.

• Documented due diligence: every lot determination has a record, a reviewer, and a date
• Verified lab testing: ISO/IEC 17025 PCB, dioxin, and methylmercury results (no conflicts of interest)
• Traceable decisions: species → refiner → crude lot → finished lot → determination
• Structured system: a real management system plaintiff attorneys recognize

Managed Service vs. DIY

• Managed service (Consultare Inc. Group): hands-off execution, expert-managed refiner monitoring, monthly reporting; best for non-GOED brands scaling into California retail
• DIY (SystemsBuilder.pro): self-managed execution with artifact library access; best for established brands with in-house QA depth

Your Risk Profile

• Documented precedent: the 2010 multi-defendant lawsuit created a proven plaintiff playbook
• Fat-bound toxins: PCBs, dioxins, and methylmercury concentrate in fish fat—the product is the concentrator
• Consent-judgment gap: outside the GOED settlement, plaintiffs may argue default-zero thresholds unless you establish your own safe-harbor file
• Brand exposure: “pharmaceutical-grade” positioning is directly undercut by “just-in-case” warnings